Cargando…

In Vitro Activity of Meropenem-Vaborbactam against Clinical Isolates of KPC-Positive Enterobacteriaceae

Vaborbactam (formerly RPX7009) is a novel inhibitor of serine β-lactamases, including Ambler class A carbapenemases, such as KPCs. The current study evaluated the in vitro activity of the combination agent meropenem-vaborbactam against a global collection of 991 isolates of KPC-positive Enterobacter...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hackel, Meredith A., Lomovskaya, Olga, Dudley, Michael N., Karlowsky, James A., Sahm, Daniel F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Microbiology 2017
Materias:	Susceptibility
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5740317/ https://www.ncbi.nlm.nih.gov/pubmed/29084745 http://dx.doi.org/10.1128/AAC.01904-17

Ejemplares similares

In Vitro Activity of Ceftibuten/VNRX-5236 against Urinary Tract Infection Isolates of Antimicrobial-Resistant Enterobacterales
por: Karlowsky, James A., et al.
Publicado: (2022)

In Vitro Activity of Ceftibuten-Avibactam against β-Lactamase-Positive Enterobacterales from the ATLAS Global Surveillance Program
por: Karlowsky, James A., et al.
Publicado: (2023)

In Vitro Activity of Gepotidacin against Gram-Negative and Gram-Positive Anaerobes
por: Hackel, Meredith A., et al.
Publicado: (2022)

In Vitro Activity of the Siderophore Cephalosporin, Cefiderocol, against Carbapenem-Nonsusceptible and Multidrug-Resistant Isolates of Gram-Negative Bacilli Collected Worldwide in 2014 to 2016
por: Hackel, Meredith A., et al.
Publicado: (2018)

Meropenem-Vaborbactam Activity against Carbapenem-Resistant Enterobacterales Isolates Collected in U.S. Hospitals during 2016 to 2018
por: Castanheira, Mariana, et al.
Publicado: (2020)

In Vitro Activity of the Siderophore Cephalosporin, Cefiderocol, against a Recent Collection of Clinically Relevant Gram-Negative Bacilli from North America and Europe, Including Carbapenem-Nonsusceptible Isolates (SIDERO-WT-2014 Study)
por: Hackel, Meredith A., et al.
Publicado: (2017)

In Vitro Activity of Sulbactam-Durlobactam against Global Isolates of Acinetobacter baumannii-calcoaceticus Complex Collected from 2016 to 2021
por: Karlowsky, James A., et al.
Publicado: (2022)

In Vitro Susceptibility of Gram-Negative Pathogens to Cefiderocol in Five Consecutive Annual Multinational SIDERO-WT Surveillance Studies, 2014 to 2019
por: Karlowsky, James A., et al.
Publicado: (2022)

In Vitro Activity of Cefepime-Taniborbactam and Comparators against Clinical Isolates of Gram-Negative Bacilli from 2018 to 2020: Results from the Global Evaluation of Antimicrobial Resistance via Surveillance (GEARS) Program
por: Karlowsky, James A., et al.
Publicado: (2022)

Activity of Meropenem-Vaborbactam Against Enterobacteriaceae Isolates Carrying bla(KPC) Collected Worldwide
por: Castanheira, Mariana, et al.
Publicado: (2017)

Meropenem-Vaborbactam Resistance Selection, Resistance Prevention, and Molecular Mechanisms in Mutants of KPC-Producing Klebsiella pneumoniae
por: Sun, Dongxu, et al.
Publicado: (2017)

Novel Specific Metallo-β-Lactamase Inhibitor ANT2681 Restores Meropenem Activity to Clinically Effective Levels against NDM-Positive Enterobacterales
por: Zalacain, Magdalena, et al.
Publicado: (2021)

In Vitro Activity of Isavuconazole and Comparators against Clinical Isolates of the Mucorales Order
por: Arendrup, Maiken Cavling, et al.
Publicado: (2015)

Potency of Omadacycline against Mycobacteroides abscessus Clinical Isolates In Vitro and in a Mouse Model of Pulmonary Infection
por: Nicklas, Danielle A., et al.
Publicado: (2022)

Comparative In Vitro Activities of SMT19969, a New Antimicrobial Agent, against Clostridium difficile and 350 Gram-Positive and Gram-Negative Aerobic and Anaerobic Intestinal Flora Isolates
por: Goldstein, Ellie J. C., et al.
Publicado: (2013)

1378. Evaluation of the In vitro Activity of Meropenem-Vaborbactam Against Carbapenem-Resistant Enterobacteriaceae, Including Isolates Resistant to Ceftazidime–Avibactam
por: Wilson, William R, et al.
Publicado: (2018)

In Vitro Activity of Chlorhexidine Compared with Seven Antifungal Agents against 98 Fusarium Isolates Recovered from Fungal Keratitis Patients
por: Oliveira dos Santos, Claudy, et al.
Publicado: (2019)

1580. Colistin Potentiates the In Vitro Activity of Meropenem–Vaborbactam (M/V) Against Some, but not All KPC-producing Klebsiella pneumoniae (KPC-Kp)
por: Jones, Chelsea E, et al.
Publicado: (2019)

In Vitro Activity of Ertapenem against Neisseria gonorrhoeae Clinical Isolates with Decreased Susceptibility or Resistance to Extended-Spectrum Cephalosporins in Nanjing, China (2013 to 2019)
por: Li, Xuechun, et al.
Publicado: (2022)

In Vitro Activities of MCB3681 and Eight Comparators against Clostridium difficile Isolates with Known Ribotypes and Diverse Geographical Spread
por: Freeman, Jane, et al.
Publicado: (2017)

In Vitro pH Activity of Ibrexafungerp against Fluconazole-Susceptible and -Resistant Candida Isolates from Women with Vulvovaginal Candidiasis
por: Sobel, Jack D., et al.
Publicado: (2021)

Vaborbactam: Spectrum of Beta-Lactamase Inhibition and Impact of Resistance Mechanisms on Activity in Enterobacteriaceae
por: Lomovskaya, Olga, et al.
Publicado: (2017)

Impact of ompk36 genotype and KPC subtype on the in vitro activity of ceftazidime/avibactam, imipenem/relebactam and meropenem/vaborbactam against KPC-producing K. pneumoniae clinical isolates
por: Rogers, Tara M, et al.
Publicado: (2023)

Activity of Cefiderocol and Comparators against Isolates from Cancer Patients
por: Rolston, Kenneth V. I., et al.
Publicado: (2020)

1603. Comparison of Ceftolozane/Tazobactam, Ceftazidime/Avibactam, and Meropenem/Vaborbactam Activity Against P. aeruginosa: A Multicenter Evaluation
por: Moise, Pamela, et al.
Publicado: (2020)

Development and Validation of an In Vitro Resazurin-Based Susceptibility Assay against Madurella mycetomatis
por: Abd Algaffar, S. O., et al.
Publicado: (2021)

In Vitro and Intracellular Activities of Omadacycline against Legionella pneumophila
por: Dubois, Jacques, et al.
Publicado: (2020)

Overview of meropenem-vaborbactam and newer antimicrobial agents for the treatment of carbapenem-resistant Enterobacteriaceae
por: Petty, Lindsay A, et al.
Publicado: (2018)

Vancomycin and Clarithromycin Show Synergy against Mycobacterium abscessus In Vitro
por: Mukherjee, Devika, et al.
Publicado: (2017)

In Vitro Activity of Delafloxacin against Contemporary Bacterial Pathogens from the United States and Europe, 2014
por: Pfaller, M. A., et al.
Publicado: (2017)

In Vitro Activity of Solithromycin against Bordetella pertussis, an Emerging Respiratory Pathogen
por: Hardy, Dwight J., et al.
Publicado: (2016)

Susceptibility Trends of Zoliflodacin against Multidrug-Resistant Neisseria gonorrhoeae Clinical Isolates in Nanjing, China, 2014 to 2018
por: Le, Wenjing, et al.
Publicado: (2021)

Potency of Vaborbactam Is Less Affected than That of Avibactam in Strains Producing KPC-2 Mutations That Confer Resistance to Ceftazidime-Avibactam
por: Tsivkovski, Ruslan, et al.
Publicado: (2020)

Turning the Tide against Antibiotic Resistance by Evaluating Novel, Halogenated Phenazine, Quinoline, and NH125 Compounds against Ureaplasma Species Clinical Isolates and Mycoplasma Type Strains
por: Valentine-King, Marissa A., et al.
Publicado: (2019)

In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, against Multidrug-Resistant Gram-Negative Bacteria
por: Mushtaq, Shazad, et al.
Publicado: (2020)

Activity of a Long-Acting Echinocandin, Rezafungin, and Comparator Antifungal Agents Tested against Contemporary Invasive Fungal Isolates (SENTRY Program, 2016 to 2018)
por: Pfaller, Michael A., et al.
Publicado: (2020)

Activity of Telavancin against Staphylococcus aureus Isolates, Including Those with Decreased Susceptibility to Ceftaroline, from Cystic Fibrosis Patients
por: Roch, Melanie, et al.
Publicado: (2018)

Biochemical Activity of Vaborbactam
por: Tsivkovski, Ruslan, et al.
Publicado: (2020)

1618. Meropenem-vaborbactam vs standard of care for multidrug resistant carbapenem-resistant Enterobacteriaceae
por: Misikir, Helina, et al.
Publicado: (2020)

Effect and Safety of Meropenem–Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial
por: Wunderink, Richard G., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_k43liaidn47nfdhgektq9qgjmv